Transcriptomic signature of response to vedolizumab in patients with moderate-to-severe ulcerative colitis: Results from an international, multicentre, retrospective cohort study

被引：0
|
作者：
Linggi, B. [1 ]
Salas, A. [2 ,3 ]
Veny, M. [2 ,3 ]
Borowski, K. [4 ]
Silverberg, M. S. [4 ,5 ]
Milgrom, R. [4 ]
Stempak, J. [4 ]
Boland, B. [6 ]
Eckmann, L. [6 ]
Smith, M. I. [1 ]
Parker, C. E. [1 ]
Jairath, V. [1 ,7 ,8 ]
Teft, W. [1 ]
Vande Casteele, N. [1 ,6 ]
机构：
[1] Aliment Inc, Med Resesarch & Dev, London, ON, Canada
[2] Fundacio Recerca Clin Barcelona FRCB IDIBAPS Hosp, Inflammatory Bowel Dis Unit, Barcelona, Spain
[3] Ctr Invest Biomed Red Enfermedades Hepat & Digest, Inflammatory Bowel Dis Unit, Barcelona, Spain
[4] Sinai Hlth Syst, Zane Cohen Ctr Digest Dis, Lunenfeld Tanenbaum Res Inst, Toronto, ON, Canada
[5] Univ Toronto, Div Gastroenterol, Mt Sinai Hosp, Toronto, ON, Canada
[6] Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA
[7] Western Univ, Dept Epidemiol & Biostat, London, ON, Canada
[8] Western Univ, Dept Med, London, ON, Canada
来源：
JOURNAL OF CROHNS & COLITIS | 2024年 / 18卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
OP40
引用
收藏
页码：I71 / I71
页数：1
相关论文
共 50 条
  • [1] TRANSCRIPTOMIC SIGNATURE OF RESPONSE TO VEDOLIZUMAB IN PATIENTS WITH MODERATE-TO-SEVERE ULCERATIVE COLITIS: RESULTS FROM AN INTERNATIONAL, MULTICENTER, RETROSPECTIVE COHORT STUDY
    Linggi, Bryan
    Salas, Azucena
    Veny, Marisol
    Borowski, Krzysztof
    Silverberg, Mark S.
    Milgrom, Raquel
    Stempak, Joanne
    Boland, Brigid
    Eckmann, Lars
    Smith, Michelle I.
    Parker, Claire E.
    Jairath, Vipul
    Teft, Wendy
    Vande Casteele, Niels
    GASTROENTEROLOGY, 2024, 166 (05) : S1114 - S1114
  • [2] Vedolizumab versus Adalimumab for Moderate-to-Severe Ulcerative Colitis
    Sands, Bruce E.
    Peyrin-Biroulet, Laurent
    Loftus, Edward V., Jr.
    Danese, Silvio
    Colombel, Jean-Frederic
    Toruner, Murat
    Jonaitis, Laimas
    Abhyankar, Brihad
    Chen, Jingjing
    Rogers, Raquel
    Lirio, Richard A.
    Bornstein, Jeffrey D.
    Schreiber, Stefan
    NEW ENGLAND JOURNAL OF MEDICINE, 2019, 381 (13): : 1215 - 1226
  • [3] Vedolizumab versus adalimumab for moderate-to-severe ulcerative colitis
    Tribich, Samuel
    Maurice, James
    FRONTLINE GASTROENTEROLOGY, 2020, 11 (02) : 173 - 173
  • [4] Vedolizumab versus Adalimumab for Moderate-to-Severe Ulcerative Colitis
    Biemans, Vince B. C.
    Hoentjen, Frank
    Pierik, Marieke J.
    NEW ENGLAND JOURNAL OF MEDICINE, 2020, 382 (01): : 92 - 92
  • [5] Sustained Clinical Remission With Vedolizumab in Patients With Moderate-to-Severe Ulcerative Colitis
    Feagan, Brian G.
    Schreiber, Stefan
    Wolf, Douglas C.
    Axler, Jeffrey L.
    Kaviya, Arpeat
    James, Alexandra
    Curtis, Rebecca I.
    Geransar, Parnia
    Stallmach, Andreas
    Ehehalt, Robert
    Bokemeyer, Bernd
    Khalid, Javaria Mona
    O'Byrne, Sharon
    INFLAMMATORY BOWEL DISEASES, 2019, 25 (06) : 1028 - 1035
  • [6] Effectiveness and safety of vedolizumab and infliximab in biologic-naïve patients with moderate-to-severe ulcerative colitis: A multicenter, retrospective cohort study
    Meng, Rui Ping
    Huang, Bao Bao
    Wei, Yan Ling
    Lyu, Lin
    Yang, Huan
    Liu, Cheng
    Zhou, Hong Li
    Liao, Xi Ping
    Zhou, Jian Yun
    Xie, Xia
    JOURNAL OF DIGESTIVE DISEASES, 2024, 25 (04) : 230 - 237
  • [7] Comparative efficacy of vedolizumab and infliximab in patients with moderate-to-severe ulcerative colitis: a multicenter real world cohort study
    Sun, Y.
    Yang, H.
    JOURNAL OF CROHNS & COLITIS, 2025, 19 : i1555 - i1555
  • [8] Vedolizumab versus Adalimumab for Moderate-to-Severe Ulcerative Colitis REPLY
    Sands, Bruce E.
    Schreiber, Stefan
    Lirio, Richard A.
    NEW ENGLAND JOURNAL OF MEDICINE, 2020, 382 (01): : 93 - 94
  • [9] The role of vedolizumab in patients with moderate-to-severe Crohn's disease and ulcerative colitis
    Shahidi, Neal
    Bressler, Brian
    Panaccione, Remo
    THERAPEUTIC ADVANCES IN GASTROENTEROLOGY, 2016, 9 (03) : 330 - 338
  • [10] Pharmacokinetics and exposure-response relationships of golimumab in paediatric patients with moderate-to-severe ulcerative colitis: results from a multicentre open-label study
    Adedokun, O. J.
    Chan, D.
    Padgett, L.
    Xu, Y.
    Hyams, J.
    Turner, D.
    Xu, Z.
    Davis, H.
    Strauss, R.
    JOURNAL OF CROHNS & COLITIS, 2016, 10 : S62 - S63
12345